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 Severe early-onset fetal growth restriction (FGR) is an untreatable condition associated with 
significant mortality and morbidity for the fetus and neonate. There has been growing interest in 
novel therapies such as nitic oxide donors/promotors to improve placental function and outcomes 
for these high-risk pregnancies. The recently published STRIDER UK trial was designed to test the 
effectiveness of sildenafil (25mg three times a day) versus placebo at prolonging gestation in severe 
early-onset FGR [1].  
The STRIDER trials are a series of international randomised controlled studies with the goal of 
assessing the ability of sildenafil to improve pregnancy outcome in FGR. Five studies were initially 
planned (UK, New Zealand/Australia, Netherlands, Republic of Ireland and Canada), each with 
slightly different eligibility criteria and protocols. However, all studies agreed to use a centralised 
data management system to facilitate a pre-planned individual patient data meta-analysis based on 
an agreed protocol [2]. 
The STRIDER UK trial was the first to be completed and showed no beneficial effect of sildenafil on 
any outcome but also no significant difference in harm when compared to placebo. The trial 
reaffirmed that this is a very high-risk cohort with fetal demise occurring in 31% of pregnancies 
(21/70 sildenafil, 22/65 placebo) with a further 18% of infants suffering a neonatal death (10/49 
sildenafil and 7/43 placebo). 
Subsequently, the New Zealand/Australia trial was completed and showed similar results 
(unpublished). More recently the Dutch STRIDER trial was halted after 183 women were recruited; 
this was in response to concerns about a higher than expected neonatal mortality (19/71 sildenafil 
vs 9/63 placebo) and high rates of persistent pulmonary hypertension of the newborn (PPHN) in the 
sildenafil arm (17/64 sildenafil vs 3/58 placebo). In addition, there were concerns about likely futility 
in terms of being able to demonstrate an improvement in the primary outcome. Naturally, these 
findings raised significant concerns globally [3, 4].  
The excess neonatal mortality of the Dutch trial, although not statistically significant, is a cause for 
concern, particularly as the data look consistent across the three trials (Figure 1). This will be further 
explored in the forthcoming IPD meta-analysis [2]  
In light of these concerns, we have reviewed the STRIDER UK trial mortality and pathology data and 
present it here in order to complement the data already in the public domain (Table 1). 
Unfortunately, post mortem and placental histology data are not available for all fetal and neonatal 
deaths. Three cases of fetal death (1 sildenafil and 2 placebo) have been excluded as these 
pregnancies were terminated due to severe early-onset FGR or related maternal conditions (HELLP 
syndrome).  
There was a slight increase in time on sildenafil treatment for women with a fetal death compared to 
those on placebo, but the relevance of this difference is at present uncertain. Gestation and 
birthweight of stillborn infants were similar in the two groups. Most neonatal deaths occurred after 
the first week of life. Almost universally, post-mortem examinations showed features of chronic 
hypoxia only. Only two cases (one sildenafil and one placebo) were reported as being complicated by 
PPHN. 
Nearly all placental pathology findings showed a spectrum of vascular under perfusion, characterised 
by maladapted maternal vessels, fibrin deposition, syncytial knotting, villous hypoplasia or 
infarctions. We observed an incidence of chronic histiocytic intervillositis (CHI) of 15%, which is 
similar to the 16% reported in a similar population by Kingdom et al. [5]. 
In conclusion, we observed no obvious differences in clinically relevant pathological or histological 
findings between sildenafil or placebo arms of the STRIDER UK trial in pregnancies complicated 
either by fetal or neonatal death. The histological and post-mortem findings were in keeping with 
placental disease and chronic fetal hypoxia.  
Whilst there appears to be no benefit from the use of sildenafil in pregnancies complicated by 
severe early-onset FGR, the possibility of excess neonatal mortality and the possible reasons for this 
warrant further study. We anticipate that our planned IPD meta-analysis [2] will provide further 
important insights in this area.   
 
Table 1 
a. FETAL DEATHS 
 Sildenafil 
n=20 
Placebo 
n=20 
Gestational Age at IUD 
< 24 weeks 
24 - 28 weeks 
≥ 29 weeks 
 
1 (5%) 
18 (90%) 
1 (5%) 
 
2 (10%) 
17 (85%) 
1 (5%) 
Birthweight 
< 500g 
 
14 (70%) 
 
18 (90%) 
Time on Treatment 
≥ 7 days 
 
19 (95%) 
 
13 (65%) 
IUD whilst on Treatment 17 (85%) 15 (75%) 
Histological Features (non-
exclusive) 
• Chronic Histiocytic 
Intervillositis (CHI) 
• Placental 
underperfusion 
(infarcts, villous 
hypoplasia, fibrin etc.) 
• Chorioamnionitis 
n=17  
 
4 (24%) 
 
13 (76%) 
 
 
1 (6%) 
n=11  
 
0 
 
11 (100%) 
 
 
0 
Post Mortem Features 
• Chronic ischaemic 
changes (adrenal lipid, 
hypoxic neurons, 
thymic depletion etc.) 
• Other 
n=5  
 
5 (100%) 
 
0 
n=5  
 
4 (80%) 
 
1 (20%) 
b. NEONATAL DEATH 
 Sildenafil Placebo 
n=10 n=7 
Gestational Age at Birth 
< 26 weeks 
≥ 26 weeks 
 
2 (20%) 
8 (80%) 
 
0 
7 (100%) 
Birthweight 
< 500g 
≥ 500g  
 
1 (10%) 
9 (90%) 
 
3 (43%) 
4 (57%) 
Age at Death 
≥ 7 days 
 
7 (70%) 
 
4 (57%) 
On Treatment at Decision to 
Deliver 
 
9 (90%) 
 
5 (71%) 
Histological Features (non-
exclusive) 
• Chronic Histiocytic 
Intervillositis (CHI) 
• Placental 
underperfusion 
(infarcts, villous 
hypoplasia, fibrin etc.) 
• Chorioamnionitis 
n=3  
 
0 
 
3 (100%) 
 
 
0 
n=3  
 
1 (33%) 
 
2 (66%) 
 
 
0 
Post Mortem Features 
• Chronic ischaemic 
changes (adrenal lipid, 
hypoxic neurons, 
thymic depletion etc.) 
• Other 
n=0 
 
0 
 
0 
n=2 
 
1 (50%) 
 
1 (50%) 
Evidence of Pulmonary 
Hypertension 
1 1 
 
Figure 1 
Forest Plot of publicly presented data on neonatal deaths from the three completed STRIDER trials 
(UK, New Zealand/Australia and Netherlands). 
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